ANAPTYSBIO, INC (ANAB) Form 10-Q — May 12, 2026
AnaptysBio, Inc. reported a net loss of $52.884 million for the quarter ended March 31, 2026, compared to a net loss of $39.329 million in the same period of 2025. The increase in net loss is primarily due to higher general and administrative expenses and non-cash interest expense. The company recognized $25.556 million in royalty revenue during the quarter, primarily from GSK's sales of Jemperli and Zejula.
Key figures
- Revenue
- 25556
- Total Debt
- 263742
- Cash Position
- 248469
- Interest income
- 2653
- Royalty revenue
- 25556
- Total operating expenses
- 60193
- Non cash interest expense
- 20859
- Research and development expenses
- 33991
- General and administrative expenses
- 26202
Price after filing
1 day: -4.4%7 days: -8.9%30 days: -20.6%
Close on the filing date to close N calendar days later (from $65.58). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.